Clarus Securities started coverage on shares of Aphria (NYSE:APHA) in a research note issued to investors on Tuesday morning, AnalystRatings.com reports. The brokerage issued a buy rating and a $22.75 target price on the stock.

“We had previously assumed a run-rate of ~$865MM by the end of CY2020; we are now in line with management’s target.”,” the firm’s analyst commented.

A number of other equities analysts have also weighed in on the stock. Cormark set a $15.00 target price on shares of Aphria and gave the stock a buy rating in a research note on Saturday, February 2nd. CIBC initiated coverage on shares of Aphria in a research note on Friday, January 18th. They issued a neutral rating for the company. Seaport Global Securities initiated coverage on shares of Aphria in a research note on Thursday, February 21st. They set a buy rating and a $18.00 price objective for the company. Finally, ValuEngine upgraded shares of Aphria from a hold rating to a buy rating in a research note on Monday, April 1st. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of Buy and a consensus target price of $15.69.

Shares of NYSE APHA opened at $7.65 on Tuesday. The firm has a market capitalization of $1.96 billion, a P/E ratio of 54.64 and a beta of 4.08. Aphria has a 1-year low of $3.75 and a 1-year high of $16.86.

Several institutional investors have recently bought and sold shares of the company. Winslow Evans & Crocker Inc. purchased a new stake in shares of Aphria in the fourth quarter valued at $28,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Aphria in the fourth quarter valued at $74,000. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Aphria in the fourth quarter valued at $77,000. Wedbush Securities Inc. purchased a new stake in shares of Aphria in the fourth quarter valued at $66,000. Finally, Intercontinental Wealth Advisors LLC purchased a new stake in shares of Aphria in the fourth quarter valued at $28,000. Institutional investors own 10.39% of the company’s stock.

About Aphria

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Further Reading: How is an ETF different from a mutual fund?

Analyst Recommendations for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.